These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34286178)

  • 1. Impact of
    Kiefer LS; Sekler J; Gückel B; Kraus MS; la Fougère C; Nikolaou K; Bitzer M; Gatidis S; Pfannenberg C
    BJR Open; 2021; 3(1):20210008. PubMed ID: 34286178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Pre-therapeutic (18)F-FDG PET/CT in Guiding the Treatment Strategy and Predicting Prognosis in Patients with Esophageal Carcinoma.
    Tan TH; Boey CY; Lee BN
    Asia Ocean J Nucl Med Biol; 2016; 4(2):59-65. PubMed ID: 27408893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
    Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.
    Goense L; van Rossum PS; Reitsma JB; Lam MG; Meijer GJ; van Vulpen M; Ruurda JP; van Hillegersberg R
    J Nucl Med; 2015 Jul; 56(7):995-1002. PubMed ID: 25952733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How [18F]-FDG-PET/CT Affects Clinical Management of Patients with Germ Cell Tumors in the Real World.
    Liang C; Sekler J; Gückel B; Pfannenberg C; Dittmann H; Seith F; Amend B; Nikolaou K; Reinert CP
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany.
    Pfannenberg C; Gueckel B; Wang L; Gatidis S; Olthof SC; Vach W; Reimold M; la Fougere C; Nikolaou K; Martus P
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):54-64. PubMed ID: 30269155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24].
    See WA
    Urol Oncol; 2014 Nov; 32(8):1350. PubMed ID: 25488385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
    Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of PET/CT on clinical management in patients with cancer of unknown primary-a PET/CT registry study.
    Reinert CP; Sekler J; la Fougère C; Pfannenberg C; Gatidis S
    Eur Radiol; 2020 Mar; 30(3):1325-1333. PubMed ID: 31728688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (11)C-Choline and FDG PET/CT Imaging of Primary Cholangiocarcinoma: A Comparative Analysis.
    Chotipanich C; Promteangtrong C; Kunawudhi A; Chanwat R; Sricharunrat T; Suratako S; Wongsa P
    Asia Ocean J Nucl Med Biol; 2015; 3(1):18-25. PubMed ID: 27408877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.
    Povoski SP; Hall NC; Murrey DA; Wright CL; Martin EW
    BMC Cancer; 2015 May; 15():378. PubMed ID: 25953144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ¹⁸F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?
    Bilici A; Ustaalioglu BB; Seker M; Kefeli U; Canpolat N; Tekinsoy B; Ozugur S; Gumus M
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):64-73. PubMed ID: 20838995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Yu HN; Liu L; Chen QS; He Q; Li YS; Wang Y; Gao S
    Orthop Surg; 2021 May; 13(3):791-798. PubMed ID: 33709632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.
    Robertson NL; Hricak H; Sonoda Y; Sosa RE; Benz M; Lyons G; Abu-Rustum NR; Sala E; Vargas HA
    Gynecol Oncol; 2016 Mar; 140(3):420-4. PubMed ID: 26790773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
    Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
    J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and prognostic value of
    Albano D; Zizioli V; Odicino F; Giubbini R; Bertagna F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):87-93. PubMed ID: 30573388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 29. F-18 FDG PET for Suspected or Confirmed Regional Recurrence of Colon Cancer. A Prospective Study of Impact and Outcome.
    Kalff V; Hicks R; Ware R; Binns D; McKenzie A
    Clin Positron Imaging; 2000 Jul; 3(4):183. PubMed ID: 11150786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.